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Endothelial progenitor cell therapy and stem cell
therapy have been proposed in regeneration of acute
myocardial infarction (AMI). In the previous issue of
Stem Cell Research & Therapy, Lamirault and colleagues
described a strong analysis of progenitors in blood
and bone marrow of patients collected after AMI, and
correlated these levels to bone marrow mononuclear
cell (BM-MNC) therapy efficacy and smoking status.
The main results are that BM-MNCs can override
smoking alteration in endothelial lineage and confirm
that endothelial progenitor cells are probably not by
themselves the active component of BM-MNC in AMI.
This paper allows one to better appreciate the cellular
complexity of cell therapy approach in AMI.tients with myeloproliferative disorders [3]. This differentEndothelial progenitor cell (EPC) therapy and stem cell
therapy have been proposed in regeneration of myocar-
dial infarction and peripheral arterial disease. However,
there remains an ongoing need to understand what
could be the cellular active component appropriate for
each clinical situation to make this cell therapy approach
impossible to circumvent. In the previous issue of Stem
Cell Research & Therapy, Lamirault and colleagues de-
scribed a strong analysis of hematopoietic progenitors
and EPC in blood and bone marrow (BM) of patients
collected after acute myocardial infarction (AMI), and
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2014The first insight from this study is the specific impair-
ment of the endothelial lineage in active smokers.
Indeed, the authors described BM activation during the
days following AMI whereas EPC numbers were found
lower in active smokers, suggesting a specific lack of acti-
vation of the endothelial lineage [1]. This is not the first
description of a specific EPC impairment and/or lack of
mobilization. Indeed, our group in 2008 described a defect
in EPC mobilization in the context of extracorporeal
circulation in patients having numerous cardiovascular
risk factors [2], while the hematopoietic lineage was
strongly enhanced whatever the risk factor status.
These results are not in favor of a mixed lineage between
hematopoietic and endothelial lineages and the hemangio-
blast existence in adults. Indeed, EPCs have been described
as clonally different from hematopoietic progenitors in pa-
ontogeny and the presence of clonogenic endothelial cells
extracted from umbilical cord blood or lung led Yoder to
suggest that EPCs could have a vascular origin [3]. This
hypothesis led us to think that EPCs could be efficiently
mobilized after vascular stimulation induced by local ische-
mia. However, because local ischemia does not mobilize
any subtypes of EPCs [4], the origin and regulation of EPCs
remain controversial and not fully understood. Finally, we
have to carefully conclude that since EPCs isolated from
smokers, despite the same level in blood as nonsmokers,
have increased DNA damage and senescence [5]. This
could explain the discrepancy between EPC numbers and
an absence of correlation with efficacy.
The second highlight of this study is that cardiac BM
cell therapy overrides EPC impairment observed in AMI
patients. The cell subset responsible for the beneficial
effects of BM cell therapy are not yet identified, but a
multitude of studies have been published and have dem-
onstrated that intracoronary BM‐MNC delivery led to aThe licensee has exclusive rights to distribute this article, in any medium, for 12
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by/2.0), which permits unrestricted use, distribution, and reproduction in any
ly cited.
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However, most of these trials did not have real biological
exploration in parallel to BM‐MNC therapy and several
remaining questions exist about the active component
and patient’s eligible for BM cell therapy.
Although Lamirault and colleagues’ results shows an
absence of correlation between the EPC level and
improvement after BM-MNC injection that is descriptive,
the findings from this study provide strong evidence that,
despite EPC involvement in physiological regeneration due
to correlation with the LVEF in placebo group patients,
EPCs are probably not the cell type responsible for clinical
improvement in the BM-MNC therapy approach. This re-
sult is in accordance with several previous hypotheses. First,
strong data from preclinical models suggest that BM-
MNCs do not differentiate into endothelial cells, and that
their paracrine effect is most probably responsible for the
angiogenic process [6]. Second, the correlation previously
described with BM-MNC efficacy has been achieved with
angiogenic cells not able to build vessels by themselves and
different from real vasculogenic EPCs [7]. Thus, the more
we know about EPCs, the more evidence seems to discredit
them as the sole active component.
A recent meta-analysis found that younger patients and
patients with a more severely depressed LVEF at baseline
benefit from this adjunctive therapy and also 5 to 7 days
after AMI produced a superior improvement in global
cardiac function (LVEF) when compared with an earlier or
delayed delivery time [8]. However, the time lag of a few
days between myocardial infarction and treatment excludes
the preparation of cell therapy products from cells purified
following expansion in vitro as mesenchymal stem cells or
EPCs. Mesenchymal stem cells induce blood flow recovery
in vivo to the same degree as in healthy controls, in
contrast to the reduced ability that has been described for
BM-MNCs and EPCs from patients with cardiovascular
disorders [9] – thus mesenchymal stem cells should be a
good candidate for cell therapy. So, despite the observation
that BM‐MNCs secrete lower amounts of angiogenic and
anti-apoptotic growth factors than the mesenchymal stem
cell subtype [10], BM-MNCs are probably the best cell
therapy product for AMI.
In conclusion, Lamirault and colleagues fill a gap in our
knowledge by identifying in a large biological study associ-
ated with a cell therapy trial that BM-MNCs can override
smoking alteration in endothelial lineage. This result allows
us to confirm that EPCs are probably not by themselves
the active component of BM-MNCs in AMI, and contrib-
utes to better appreciation of the cellular complexity of the
cell therapy approach in AMI.
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